On October 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, Inc., marking another important advancement for the FSHD community. With this acquisition, Novartis, one of the world’s largest and most established pharmaceutical companies, now has two therapies for FSHD in its development pipeline. The alignment deepens Novartis and Avidity’ ongoing commitments to translating innovation into meaningful outcomes for people living with FSHD.
The FSHD Society has been working with Novartis since it acquired Kate Therapeutics last year, and we are encouraged to see its continued investment and growing leadership in FSHD research and development. This consolidation of expertise signals strong momentum toward bringing safe and effective treatments to people living with FSHD.
Avidity’s innovative work in muscle-directed RNA therapeutics has played an important role in advancing FSHD research, and we appreciate its contributions to the field. The FSHD Society also acknowledges the productive collaborations we have enjoyed with Avidity—from scientific dialogue and patient-voice forums to shared advocacy efforts. We look forward to seeing that progress continue under Novartis’s stewardship, supported by its global resources and commitment to translating scientific discovery into real-world outcomes for people living with FSHD.
We congratulate Avidity Biosciences on this development and are excited to continue working with Novartis to advance safe and effective therapies for FSHD, engage patients and families in research and clinical trial design, and ensure equitable access to innovation across the global FSHD community.
Read the full press release from Novartis here:
English English 
العربية
Español de México
Français du Canada
简体中文
